Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models
Mandana T. Manzari(Duke University), Ashutosh Chilkoti(Duke University), Joseph J. Bellucci(Duke University), Chandler E. Moore(Duke University), Suzanne E. Wardell(Duke University), Kris C. Wood(Duke University), Ryan S. Soderquist(Duke University), Kevin Lin(The University of Texas MD Anderson Cancer Center), Merve Çakır(University of California, San Francisco), Rachel N. Skelton(Duke University), Grace R. Anderson(Duke University), Xinghai Li(Duke University), M. Fèvre(Duke University), Simone A. Costa(Duke University), Mitchel Zhang(Duke University)
Cited by 15
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Probing the Ultimate Limits of Plasmonic Enhancement
|Science|2012|1.2k
The Global Phosphorylation Landscape of SARS-CoV-2 Infection
|Cell|2020|1.1k
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
|JNCI Journal of the National Cancer Institute|2006|923
Purification of recombinant proteins by fusion with thermally-responsive polypeptides
|Nature Biotechnology|1999|913